Ozempic® Babies: What To Know About Semaglutide And Pregnancy | Does It Make You More Likely To Conceive

Key Takeaways On Taking Semaglutide For Weight Loss

While semaglutide does not directly enhance fertility, its significant weight loss benefits can indirectly improve fertility prospects by restoring hormonal balance and promoting regular ovulation. What’s more, Ozempic® and other GLP-1 medications can interfere with birth control and make it ineffective, increasing the risk of unintended pregnancy. As with any medication, it is crucial to consult healthcare providers before starting treatment, especially for those planning to conceive.

At Mochi Health, we understand the challenges of weight management and are committed to providing personalized, patient-centered care. Our comprehensive weight care solutions are designed to help you achieve lasting results through manageable steps tailored to your unique health history and goals. With expert support from board-certified obesity medicine providers and a dedicated care team, you can take control of your health and ensure the safe administration of medications based on your unique health history.

Join tens of thousands of members nationwide who are taking charge of their health with Mochi Health. Discover how our personalized programs, including tailored plans, virtual visits, unlimited nutrition coaching, and 24/7 support, can make a difference in your journey.

Find out if you’re eligible for Mochi Health’s comprehensive weight care program today!

References:

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

2. Food and Drug Administration. Ozempic® (semaglutide) injection prescribing information, revised 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf

3. Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, obesity & metabolism, 19(9), 1242–1251. https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.12932

4. Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., Helms, H. C. C., Jeppesen, J. F., John, L. M., Pyke, C., Nøhr, J., Lu, T. T., Polex-Wolf, J., Prevot, V., Raun, K., Simonsen, L., … Hogendorf, W. F. J. (2020). Semaglutide lowers body weight in rodents via distributed neural pathways. JCI insight, 5(6), e133429. https://insight.jci.org/articles/view/133429

5. Deswal, R., Narwal, V., Dang, A., & Pundir, C. S. (2020). The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. Journal of human reproductive sciences, 13(4), 261–271. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/33627974/

6. Cena, H., Chiovato, L., & Nappi, R. E. (2020). Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. The Journal of clinical endocrinology and metabolism, 105(8), e2695–e2709. https://academic.oup.com/jcem/article/105/8/e2695/5842158?login=false

7. Clark, A. M., Thornley, B., Tomlinson, L., Galletley, C., & Norman, R. J. (1998). Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Human reproduction (Oxford, England), 13(6), 1502–1505. https://pubmed.ncbi.nlm.nih.gov/9688382/‍

8. Food and Drug Administrator. (n.d.-b). MOUNJAROTM (tirzepatide) injection, for subcutaneous use. Access Data FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf

This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.